The MAPK signalling pathway plays an important role in cell value-adding, differentiation, apoptosis, etc. Abnormal activation of the MAPK signalling pathway (RAS-RAF-MEK-ERK signalling pathway) is more common in gliomas, and targeted drugs against the MAPK pathway play an important role in a variety of tumour treatments, however, monotherapy is associated with the problem of tumour resistance.The MEK kinase inhibitor (MEKi) trametinib is one of these targeted agents, but its low penetration in the central nervous system limits its use in brain tumours [6]. The gene discussed is MAP2K7; the disease is neoplasm.